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Epilepsy is a disease with substantial missing heritability; despite its high genetic component, genetic association studies have
had limited success detecting common variants which influence susceptibility. In this paper, we reassess the role of common
variants on epilepsy using extensions of heritability analysis. Our data set consists of 1258 UK patients with epilepsy, of which
958 have focal epilepsy, and 5129 population control subjects, with genotypes recorded for over 4 million common single
nucleotide polymorphisms. Firstly, we show that on the liability scale, common variants collectively explain at least 26%
(standard deviation 5%) of phenotypic variation for all epilepsy and 27% (standard deviation 5%) for focal epilepsy.
Secondly we provide a new method for estimating the number of causal variants for complex traits; when applied to epilepsy,
our most optimistic estimate suggests that at least 400 variants influence disease susceptibility, with potentially many thou-
sands. Thirdly, we use bivariate analysis to assess how similar the genetic architecture of focal epilepsy is to that of non-focal
epilepsy; we demonstrate both significant differences (P = 0.004) and significant similarities (P = 0.01) between the two
subtypes, indicating that although the clinical definition of focal epilepsy does identify a genetically distinct epilepsy subtype,
there is also scope to improve the classification of epilepsy by incorporating genotypic information. Lastly, we investigate the
potential value in using genetic data to diagnose epilepsy following a single epileptic seizure; we find that a prediction model
explaining 10% of phenotypic variation could have clinical utility for deciding which single-seizure individuals are likely to
benefit from immediate anti-epileptic drug therapy.
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Introduction
Epilepsy is a common, serious neurological disease, defined by an
enduring predisposition to epileptic seizures (Fisher et al., 2005),
which across North America and Europe affects approximately five
people in every 1000 (Banerjee et al., 2009). It is a highly hetero-
geneous condition that encompasses a spectrum of clinical sub-
types, defined by EEG, seizure type and brain imaging criteria.
Although clinical classifications are constantly evolving and
remain a source of debate (Korff and Scheffer, 2013), patients
with epilepsy can be divided into one of two broad categories:
focal epilepsy, defined as seizures originating within one cerebral
hemisphere, and non-focal epilepsy, of which the majority have
generalized epilepsy and a smaller proportion are unclassifiable
(Berg et al., 2010). Where care has been taken with seizure clas-
sification, 60% of people with epilepsy are classified as focal
(Banerjee et al., 2009).
Although traditional estimates of heritability for epilepsy vary
greatly, depending on the method used, the population sampled
and the mixture of clinical subtypes considered, studies have con-
sistently demonstrated that the condition has a substantial genetic
component; estimates of heritability from twin studies typically fall
in the range 25–70% (Miller et al., 1998; Kjeldsen et al., 2001).
By contrast, the molecular genetic factors affecting common forms
of epilepsy remain poorly understood. The largest genome-wide
association study (GWAS) to date, which considered 3445
Caucasian patients with focal epilepsy and 6935 control subjects,
found no single nucleotide polymorphisms (SNPs) significantly
associated with risk (Kasperavicˇiru¯te_ et al., 2010). In a smaller
GWAS of 1087 Chinese focal patients and 3444 controls,
genome-wide significance was achieved by a single locus on
1q32.1 (minimum P = 1 108; Guo et al., 2011), whereas a
GWAS of 1527 European generalized patients and 2451 controls
reported significant loci at 2p16.1 and 17q21.32 (minimum
P = 2109 and P = 9 109, respectively; EPICURE
Consortium et al., 2012). None of these three loci have yet
been replicated in independent studies. For a minority of epilepsy
cases, rare copy number variants have been shown to confer risk
for both focal and non-focal forms of epilepsy (Dibbens et al.,
2009; de Kovel et al., 2010; Heinzen et al., 2010), whereas for
uncommon, monogenic forms of epilepsy, many causal genes
have been identified using linkage analysis or exome sequencing
of parent-offspring trios (Heinzen et al., 2012; Epi4K Consortium
et al., 2013; Hildebrand et al., 2013); however, altogether these
findings explain only a small fraction of the overall population
susceptibility of epilepsy.
To date, GWAS have predominantly focussed on marginal
(single-SNP) analyses, where each SNP is tested individually for
association with the phenotype. To allow for the large number
of SNPs being tested (from a few hundred thousand to many
millions), a SNP is only declared associated if its P-value is below
a stringent significance threshold (typically P55 108). So al-
though GWAS have successfully discovered SNPs influential for (or
which tag variants which influence) a large variety of phenotypes,
with standard sample sizes, they will struggle to detect SNPs of
moderate or weak effect. In recent years, methods have been
developed for assessing the joint influence of multiple SNPs on
phenotypes. A major advantage of these methods is that they
can appreciate the contribution of variants with effect sizes too
small to be picked up through traditional marginal analysis. In
particular, it has been shown that by applying SNP-based herit-
ability analysis to GWAS of nominally unrelated individuals, it is
possible to estimate the total variance explained by common vari-
ants (Yang et al., 2010, 2011; Speed et al., 2012), whereas by
using a bivariate extension of the method it is possible to examine
the amount of overlap between the genetic architecture of two
traits (Lee et al., 2012).
In this study, we use extensions of SNP-based heritability ana-
lysis to reconsider the impact on susceptibility to epilepsy of
common variants, defined as those with minor allele frequency
40.01, and to describe the genetic architecture of the disease.
Our data set consists of genome-wide SNP data for 1258 epilepsy
cases and 5129 population controls. Although marginal analysis
finds no individual SNPs significantly associated with susceptibility
to epilepsy, we determine that collectively common SNPs explain a
sizeable proportion of phenotypic variation: 26% [standard devi-
ation (SD) 5%] when considering all epilepsy and 27% (SD 6%)
when considering patients with focal epilepsy. These estimates
account for inflation due to population structure and genotyping
errors. By considering genome-wide distributions of heritability
that are consistent with the results from our association and her-
itability analyses, we show that epilepsy is a highly polygenic trait
with a minimum of 400 susceptibility loci, but potentially many
thousands, and that the majority of heritability resides with
loci which individually explain only a small fraction (50.04%)
of phenotypic variation. These results indicate that large meta-
analyses, involving tens of thousands of individuals, will be
required to confidently detect individual SNPs influencing suscep-
tibility to epilepsy.
One measure of the genetic similarity between two traits is ,
the correlation between SNP effect sizes for each trait:  = 1 indi-
cates the two traits have identical genetic aetiologies whereas
 = 0 indicates no overlap. Using bivariate analysis (Lee et al.,
2012), we estimate  = 0.45 for focal and non-focal epilepsy.
This result shows that there are significant differences between
the genetic architectures of the two subtypes (P = 0.004 when
testing the hypothesis  = 1), reinforcing the belief that focal
and non-focal forms of epilepsy represent distinct disorders.
However, it also demonstrates a significant overlap between
these two subtypes of epilepsy (P = 0.01 when testing  = 0);
this suggests there is scope to improve current clinical classifica-
tions, perhaps by incorporating genetic markers, which would
facilitate the identification of subtype-specific genetic associations.
Our result emphasizes the importance of considering both ‘all
epilepsy’ and its individual clinical subgroups in the search for
susceptibility loci.
Conceptually, epilepsy is said to exist after at least one unpro-
voked, non-febrile seizure and when there is a high risk of recur-
rence (Fisher et al., 2005). As 50–60% of individuals who
experience a first, unprovoked, non-febrile epileptic seizure will
never experience a second (Berg et al., 2010), on a practical
level the diagnosis of epilepsy has traditionally relied on the pres-
ence of at least two epileptic seizures, as then the chance of
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recurrence is sufficiently high (60–90%; Hauser et al., 1998).
Recently, the International League Against Epilepsy (ILAE) have
adopted a new definition of epilepsy, such that an individual
experiencing their first seizure should be considered to have epi-
lepsy if their probability of further seizures is similar to the general
recurrence risk after two seizures (Fisher et al., 2014).
Given the substantial estimates of variance explained, then with
sufficient sample size it should be possible to construct a reason-
able prediction model for epilepsy using genome-wide SNP data.
Although the low prevalence of epilepsy means that this model
would have limited value in terms of predicting which individuals
in the general population will develop epilepsy, we examine how
well they could assist the diagnosis of epilepsy for patients who
have experienced a first epileptic seizure. We find that the ability
of such a model to predict which single-seizure individuals will
have subsequent seizures depends heavily on the distribution of
liability values of individuals for whom the first seizure remains an
isolated event. In the best case scenario, we determine that to
achieve AUC (area under the receiver operating curve)40.75,
which has been considered a threshold for clinical use (Janssens
et al., 2006), it is necessary to construct a prediction model ex-
plaining 10% of phenotypic variation.
Materials and methods
Epilepsy patients were recruited to our study by epilepsy specialists at
UK epilepsy centres (Speed et al., 2014). Inclusion criteria for the
study were: (i) epilepsy patients aged 5 years or older; (ii) two or
more unprovoked, non-febrile seizures; and (iii) able to give informed
consent. Exclusion criteria were: (i) provoked seizures (e.g. alcohol); (ii)
acute symptomatic seizures (e.g. acute brain injury); and (iii) progres-
sive neurological disease (e.g. brain tumour). Patients were classified
according to ILAE guidelines (Commission on Classification and
Terminology of the ILAE, 1989; Berg et al., 2010). Epilepsy subtype
was determined by clinicians, and classified as focal, generalized or
unclassified (unclassified where there was no evidence for focal
onset either clinically or from neuroimaging, but where the EEG did
not show a generalized epileptic discharge). A breakdown of epilepsy
subtypes is provided in Supplementary Table 1.
After quality control, our data comprise 1258 UK epilepsy patients
(958 of subtype focal, 151 generalized and 149 unclassified),
combined with 5129 controls (2655 from the 1958 Birth Cohort and
2464 from the National Blood Service; The Wellcome Trust Case
Control Consortium, 2007). Before imputation, individuals were
recorded for 299 735 autosomal SNPs with minor allele frequency
40.01; after imputation against the 1000 Genome Phase I June
2011 (interim) reference panel using IMPUTE2 (The 1000 Genomes
Project Consortium, 2010; Howie et al., 2011), this number
increased to 4 238 038. Our quality control steps (detailed in full
in the Appendix) sought to exclude suspect samples, poorly genot-
yped or imputed SNPs, and apparent population outliers.
Additionally, we removed close relatedness by filtering samples so
that no pair remained with estimated kinship (computed using allelic
correlations; Astle and Balding, 2009) 42.6%, a level of relatedness
slightly lower than that expected between second cousins (Yang et al.,
2010).
Details of our statistical analyses are provided in Appendix 1.
Results
Marginal association analysis
Figure 1 presents P-values from marginal tests of association for
susceptibility to all epilepsy (1258 cases, 5129 control subjects).
We used an additive logistic regression model, including as covari-
ates sex and the five leading principal component axes (the ap-
propriate number of axes to include was determined through
heritability analysis, see below and Supplementary Fig. 1). The
genomic inflation factor is 1.05. The smallest association P-value
for any SNP is P = 1.9106, considerably above 5 108, the
conventional threshold for genome-wide significance. We had
80% power to detect a variant explaining 40.46% of liability
variation (see below for an explanation of the liability model)
and 50% power to detect a variant explaining 40.35%
(Supplementary Fig. 2) We also performed the analysis using
only focal epilepsy patients (958 cases), and using only non-
focal patients (300 cases consisting of patients with generalized
and unclassified epilepsy combined). Again, no SNPs reached
genome-wide significance (Supplementary Fig. 3); the smallest
P-values were P = 1.9106 (inflation factor 1.05) and
P = 8.2108 (inflation factor 1.01), respectively. Our results for
focal epilepsy are consistent with those of Kasperavicˇiru¯te_ et al.
(2010), who concluded there was no evidence for common SNPs
affecting focal epilepsy susceptibility with odds ratios 41.3 (their
study included our control samples). Notably, we found no sup-
port for rs2292096 within CAMSAP1 (in our analysis this SNP
had P = 0.26, whereas the minimum P across the 178 SNPs within
this gene is 0.22). The study identifying this SNP considered
focal epilepsy patients of Chinese ancestry (Guo et al., 2011)
whereas our patients are of European ancestry. We also
consider generalized epilepsy (151 cases), identifying a single locus
within SYNRG (top SNP rs116499908, P = 3.3108; inflation
factor 1.01).
Variance explained by common single
nucleotide polymorphisms
When considering a disease phenotype, it is convenient to sup-
pose an underlying liability model (Supplementary Fig. 4); this as-
sumes that case/control status is determined according to whether
or not an individual’s liability, an unobservable, normally distribu-
ted random variable, lies above or below a threshold (Falconer and
Mackay, 1996). On this scale, estimates of variance explained are
invariant to disease prevalence and study ascertainment. To esti-
mate h2L, the proportion of phenotypic liability variation which can
be attributed to common SNPs, we first use LDAK (Speed et al.,
2012) to calculate a kinship matrix based on allelic correlations
across autosomes, using an additive encoding of SNPs, with
values centred and scaled to have mean zero and variance one.
Then, including as fixed effects sex and the top five principal
component axes as used in the association analysis above, we
use restricted maximum likelihood (REML) to estimate h2
O
, the
fraction of phenotypic variation on the observed scale (cases 1,
controls 0) attributable to the kinship matrix. h2L is then related
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to h2
O
via
h2L ¼ h2o  K2 1 Kð Þ2=p 1 p
 
z2;
where K is the disease prevalence, p is the proportion of cases in
the sample, and z is the standard normal density at the liability
threshold (Dempster and Lerner, 1950; Yang et al., 2011)
(Supplementary Fig. 4). The accuracy of this transformation has
been questioned for extreme prevalences (Yang et al., 2011), so
to test its appropriateness for our study, we simulate phenotypes
with K = 0.005 and P = 1258/6387 (the values we use when ana-
lysing the phenotype all epilepsy). We find that the resulting es-
timates of h2L are on average 90% of the true values
(Supplementary Fig. 5), indicating that heritability analysis will
tend to moderately underestimate the total variance explained
on the liability scale for low prevalence diseases.
Table 1 reports our estimates of h2
O
and h2L for all epilepsy, and for
the subtypes focal and non-focal (generalized and unclassified pa-
tients combined). As expected, estimates with imputed SNPs
included are larger than those based only on genotyped SNPs, on
average by about a quarter. The final column reports h2C, which ad-
justs the corresponding estimate of h2L for inflation due to population
stratification and genotyping errors (see below). To benchmark esti-
mates of h2L, it is possible to estimate h
2
T, the total liability heritability
for each phenotype from estimates of prevalence and sibling relative
risk (Falconer and Mackay, 1996; Wray et al., 2010). Using the
values reported by Ottman et al. (1998) and Peljto et al. (2014),
we estimate for all epilepsy h2T = 32% (95% CI 24–41), for focal
epilepsy h2T = 23% (95% CI 5–43), and for non-focal epilepsy
h2T = 36% (95% CI 15–59). Despite their limited precision, the esti-
mates of h2T suggest that for each epilepsy phenotype, common SNPs
are able to explain the majority of liability heritability, and this
conclusion holds for alternative estimates of the population preva-
lence (Supplementary Table 2).
The epilepsy cases were genotyped using a lower coverage
array than the two wild-type control data sets used for this
study (Illumina 660Q as opposed to Illumina 1.2 M), so for the
main analysis we imputed case and control cohorts separately.
However, we additionally imputed all three cohorts together,
starting with the subset of SNPs present on all three arrays. The
resulting estimate for all epilepsy was h2L = 31.7%, almost identical
to our previous estimate (h2L = 31.5%), suggesting that with suf-
ficient quality control, separate imputation is not a concern (and
generally much faster). When computing kinships, LDAK adjusts
for uneven tagging (Speed et al., 2012). For comparison, we also
omitted this adjustment, following instead the method of Yang
et al. (2010). For each phenotype, the resulting estimate of h2L
based on imputed SNPs was lower than that using only genotyped
SNPs (Supplementary Table 3), a paradoxical result that demon-
strates the importance of adjusting for tagging when performing
heritability analysis. An additional benefit of the adjustment is that
for the imputed data only 7% of the 4.3 million SNPs receive a
non-zero weighting, effecting a 14-fold data reduction and speed-
up when subsequently estimating variance explained.
Inflation due to residual familial
relatedness, population structure and
genotyping errors
The reason that we require individuals to be distantly related is be-
cause we want to estimate the variance explained only by causal
variation in linkage disequilibrium with common SNPs. By contrast,
Figure 1 Manhattan plot for single SNP tests of association. Points report -log10 P-values from single-SNP tests of association for the
phenotype all epilepsy (1258 cases, 5129 controls). Red/blue points correspond to genotyped SNPs, grey to imputed. The conventional
threshold for genome-wide significance (5 108) is marked by a horizontal dashed line. Manhattan plots for the phenotypes focal, non-
focal and generalized epilepsy are provided in Supplementary Fig. 3.
Table 1 Estimates of variance explained by common SNPs
Phenotype Population Sibling Total liability Genotyped SNPs Imputed SNPs
Prevalence Relative risk Heritability, h2T h
2
O
h2L h
2
O
h2L h
2
C
All epilepsy (1258 cases) 0.005 3.3 [2.5–4.3] 32 [24–41] 31 (6) 23 (4) 42 (6) 31 (5) 26
Focal (958 cases) 0.003 2.6 [1.2–5.3] 23 [5–43] 33 (6) 27 (5) 41 (7) 33 (5) 27
Non-focal (300 cases) 0.002 4.7 [2.1–10.8] 36 [15–59] 21 (7) 38 (12) 24 (8) 46 (14) 44
For each phenotypes, we report estimates of h2
O
, the percentage of variance explained on the observed scale (cases 1, controls 0), and h2L , the corresponding estimate on the
liability scale (standard deviations provided in parentheses). h2C is obtained from h
2
L by subtracting the estimated inflation due to population stratification and genotyping
errors (see text). For comparison, h2T, the total liability heritability, is estimated for each phenotype based on the prevalence and reported estimates of sibling relative risk
(95% CI shown in square brackets).
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when closely related pairs of individuals are included, they will tend
to share long genomic regions leading to long-range tagging, and
also estimates of h2L will possibly include contributions from shared
environmental factors. Additionally, estimates will depend on the
degree of relatedness between the sampled individuals, whereas
with unrelated individuals estimates should be stable across popu-
lations (because linkage disequilibrium tends to be stable). We also
wish to avoid population differences between cases and controls;
when these are present, then variants that correlate with these dif-
ferences (for example, SNPs whose allele frequencies vary between
populations) will contribute towards estimates of variance ex-
plained, whether or not they tag true causal variation. We previ-
ously formalized a test to measure inflation of estimates of variance
explained due to residual relatedness and population structure
(Speed et al., 2012). For the phenotype all epilepsy, we calculate
that when including five principal component axes as covariates,
9% of our estimate of h2L corresponds to inflation from these
sources (i.e. in absolute terms, our estimate was inflated by
3%); the 9% value becomes 8% for focal epilepsy and 1% for
non-focal epilepsy (Supplementary Fig. 1). These results indicate
that the cases and controls are sufficiently well-matched with re-
spect to population and that estimates of variance explained are not
substantially affected by residual relatedness.
Estimates of h2L can also be inflated by genotyping errors, and
strict quality control is required when analysing binary outcomes
for which cases and controls have been genotyped separately
(Yang et al., 2011; Speed et al., 2012). In Appendix 1, we
derive a formula for how the heritability of a binary trait changes
according to relabeling or exclusion of samples. When two or
more control data sets are present, this formula allows us to esti-
mate inflation due to genotyping errors within control individuals;
we provide proof through simulation (Supplementary Fig. 6). For
‘all epilepsy’, we estimate that inflation due to genotyping errors
in controls accounts for 8% of our estimate for h2L (in absolute
terms 2%); for focal epilepsy this figure is 11%, for non-focal
epilepsy 3% (Supplementary Table 4). Although having only one
case data set prevents us from measuring inflation due to geno-
typing errors among case individuals, given that the same quality
control steps were used, we expect this to be of similar magni-
tude. Our final estimates of h2L, with these three sources of infla-
tion discounted, are h2C = 26% for all epilepsy, h
2
C = 27% for focal
epilepsy and h2C = 44% for non-focal epilepsy.
Variance explained by reported
susceptibility loci
The methodology above can also be used to estimate the variance
explained by a subset of SNPs, by using only these SNPs when con-
structing the kinship matrix. Firstly, we consider the 6003 SNPs
within 500 kb of rs2292096 (located at 1q32.1), rs13026414
(2p16.1) and rs72823592 (17q21.32), which correspond to the
three loci identified through previous GWAS (above). The estimate
of h2L is50.05%, regardless of which phenotype we consider, and in
all cases not significantly different from zero (Supplementary Table
5). Secondly, we identify a list of 85 genes implicated in previous
epilepsy studies by searching the UniProtKB database (http://www.
uniprot.org) using the keyword ‘epilepsy’. Including the 119 630
SNPs located inside or within 20 kb of the transcription start or end
sites of these genes, we estimate h2L = 3.9% (SD 1.0%) for the
phenotype all epilepsy; this estimate of variance explained is both
significantly greater than zero (P5104) and also significantly larger
than expected given the number of SNPs involved (permuted
P50.01; Supplementary Table 5), indicating that these genes do
harbour susceptibility loci, but that collectively they account for a
relatively small fraction of the total heritability of epilepsy.
Estimating the number of causal
variants
We explain how it is possible to gain insights into the number of
causal variants underlying a phenotype by considering possible
ways the total variance explained by common SNPs is distributed
across the genome. By causal variant, we mean any source of genetic
variation which affects the phenotype (here, epilepsy susceptibility).
As we are considering variation tagged by common SNPs, we expect
most of these causal variants to also be common SNPs, but this is not
necessarily the case because common SNPs will to some extent tag
other sources of variation, such as rare variants and copy number
variations (see the ‘Discussion’ section).
For Fig. 2, we base calculations on the results of our association
and heritability analysis for the phenotype all epilepsy; see
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Figure 2 Estimating the number of causal variants. We suppose
heritability is distributed over causal variants either equally
(black), uniformly (red), exponentially (green) or 2 (blue). (A) As
the number of causal variants increases (x-axis), the average
heritability of each variant decreases, and the probability of
single-SNP analysis finding no significant associations increases
(y-axis). For each distribution, our point estimates (lower bounds)
for the number of causal variants are the numbers required for
this probability to exceed 0.5 (0.05), and are marked by vertical
lines. Based on the point estimates, the histograms in B show for
each distribution how much heritability each causal variant ex-
plains. The values above bars report the proportion of variance
explained by causal variants within each tranche.
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Supplementary Fig. 7 for focal and non-focal epilepsy. We fix
the total variance explained by all causal variants at 26%. For
Fig. 2A, we vary the number of causal variants (x-axis) and the
distribution of heritability across these variants (colour), then
calculate the probability that no single variant achieves
P5 1.9 106 from single-SNP association analysis (Appendix
1). For each distribution, we record how many causal variants
are required for this probability to exceed 0.5 (our point esti-
mate) or 0.05 (our estimated lower bound). The most parsimo-
nious scenario is that all causal variants contribute equal
heritability (black line), similar to the distribution so far
observed for human height and schizophrenia (Kemper et al.,
2012), which would suggest 870 causal variants, with a min-
imum of 420. If we instead suppose the distribution of herit-
ability is uniform (red line), 1230 causal variants are required
(minimum 600); if exponential (green line), the distribution con-
sidered by Goldstein (2008), 2160 are needed (minimum 1060);
if ‘2’ (a gamma distribution with shape parameter 0.5; blue
line), the distribution that applies to heritability contributions if
effect sizes are Gaussian (Yang et al., 2010; Speed et al.,
2012), the number rises to 3390 (minimum 1650).
Given the point estimates for the number of causal variants
for epilepsy, the histograms in Fig. 2B show the spread of her-
itability for each of the four distributions. Regardless of the dis-
tribution considered, the majority of total heritability is
accounted for by variants that each explain 50.04% of pheno-
typic variation. Table 2 shows how the expected success of an
epilepsy GWAS depends on its total sample size n. For example,
if heritability is distributed exponentially with 2160 causal vari-
ants, and n is increased to 20 000, 50 000 or 100 000 (main-
taining a similar case-control ratio) we would expect to detect 6,
103 or 401 of the 2160 causal variants, explaining in total
0.3%, 4.3% or 12.2% of liability variation. The figures are simi-
lar regardless of the assumed distribution, and in all cases,
412 500 samples are required before we can expect to find
at least one causal variant, although the predicted success can
be improved by increasing the ratio of cases to controls
(Supplementary Table 6).
Overlap between subtypes
We can measure the concordance between focal and non-focal
epilepsy by , the correlation between the SNP effect sizes for
each phenotype;  close to 1 indicates that the effect sizes for
focal epilepsy are very similar to those for non-focal epilepsy, and
would suggest that the clinical divide of patients into focal and
non-focal has very little genetic basis. Using a bivariate extension
to heritability analysis (Lee et al., 2012), we estimate  = 0.45, a
value significantly lower than 1 (P = 0.007 or P = 0.00002, de-
pending on how the control datasets are matched with focal
and non-focal cases; Supplementary Table 7), indicating that pa-
tients with focal epilepsy are genetically distinct. However, our
estimate of  is also significantly greater than 0 (P = 0.02 or
P = 0.001), indicating that many causal variants are common to
both subtypes. These findings suggest that clinical classifications
could be improved upon and that at present when conducting an
epilepsy GWAS it is advisable to analyse epilepsy subtypes both
separately and together.
Prediction models based on common
single nucleotide polymorphisms
We investigated the potential for predicting an individual’s risk of
developing epilepsy using a linear prediction model constructed
from common SNPs. This model takes the form:
Gi ¼ ibjXij
where Gi is the predicted risk score for Individual i, Xij is the geno-
typic value of Individual i for SNP j, and bj is the corresponding
SNP effect size. The performance of a prediction model can be
measured by r2L, the squared correlation between each individual’s
predicted risk Gi and their liability value (r
2
L can be computed from
r2
O
, the squared correlation between Gi and case/control status,
using the transformation above). For prediction models con-
structed from common SNPs, h2L represents an upper bound on
r2L; how close performance will be to this upper bound in practice
will depend on how accurately the effect sizes can be estimated,
which in turn depends on the available sample size, the genetic
Table 2 Expected success of single-SNP analyses
Equal, 870 Causal loci n = 6387 n = 12 500 n = 20 000 n = 50 000 n = 100 000
Expected number of associations 0.1 0.6 3.9 147 710
% of variance explained 0.0 0.0 0.1 4.4 21.4
Uniform, 1230 Causal loci n = 6387 n = 12 500 n = 20 000 n = 50 000 n = 100 000
Expected number of associations 0.1 0.7 4.6 142 570
% of variance explained 0.0 0.0 0.2 4.9 17.8
Exponential, 2160 Causal loci n = 6387 n = 12 500 n = 20 000 n = 50 000 n = 100 000
Expected number of associations 0.1 0.9 5.7 103 401
% of variance explained 0.0 0.0 0.3 4.3 12.2
Chi Squared, 3390 Causal loci n = 6387 n = 12 500 n = 20 000 n = 50 000 n = 100 000
Expected number of associations 0.1 0.9 5.9 96 360
% of variance explained 0.0 0.1 0.3 4.1 11.1
For each assumed distribution of heritability across causal variants, using the corresponding point estimates for the number of causal variants, we estimate
the expected number of causal variants detected and the total proportion of liability variation these explain, for different total sample size n. We assume the
case-control ratio remains fixed at 1258:5129.
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architecture of the trait, and the performance of the estimation
method used. Even if we constructed a prediction model with r2L
close to h2L, due to the low overall prevalence of epilepsy, this
model would still have limited use in identifying individuals from
the general population likely to develop epilepsy. For example, a
prediction model with r2L = 0.3 would have AUC 0.89
(Supplementary Fig. 8), but assuming a population prevalence
of 0.005, then of the 10% (1%) of individuals with highest pre-
dicted risk, only 3.2% (9.6%) would be expected to develop
epilepsy.
By contrast, for individuals who experience a single, unpro-
voked, non-febrile seizure, the prevalence of epilepsy is much
higher (40–50%; Berg et al., 2010). We therefore explore how
well a SNP-based prediction model can distinguish single-seizure
individuals who have epilepsy (i.e. those destined to have fur-
ther seizures) from those who do not have epilepsy (i.e. for
whom the first seizure remains an isolated event). A major
factor influencing the success of our prediction model is the
distribution of liabilities of non-recurrent individuals. Figure 3A
and B show the ‘Best’ and ‘Worst’ case scenarios. Prediction will
be best when the liability distribution for single-seizure individ-
uals without epilepsy matches that of the general population
(i.e. that of individuals who never experience any seizures), as
then the difference between the average liability values for
single-seizure individuals with and without epilepsy will be great-
est. Conversely, the scenario where single-seizure individuals
without epilepsy have liabilities just below the case/control
threshold will prove most challenging.
For the best case scenario, Fig. 3C shows how prediction
accuracy depends on r2L. To achieve AUC 0.75, r
2
L = 0.1 is
required (green line). Given such a model, if we were to pick
the 10% (20%) of individuals with highest predicted risk, we
would expect 80% (75%) of these to experience a second seiz-
ure, and we would have identified 18% (33%) of the indi-
viduals that will subsequently develop epilepsy. However, under
the worst case scenario, performance is much poorer, and even
a prediction model with r2L = 0.3 would only achieve AUC 0.60
(Supplementary Fig. 8). These results demonstrate the need to
recruit to studies individuals who experience a single seizure but
do not develop epilepsy, as then it will be possible to investi-
gate which liability distribution is most appropriate, and there-
fore be more precise about the potential success of prediction
models in diagnosing epilepsy following a single epileptic
seizure.
Figure 3 Performance of prediction models for single-seizure patients. A and B illustrate the two extreme cases for the distribution of
liabilities for single-seizure individuals who do not have epilepsy. In the ‘Best Case Scenario,’ their liability distribution matches that of
population controls, while in the ‘Worst Case Scenario,’ their liabilities lie just below the case/control threshold. C and D show, again for
the Best and Worst Case Scenarios, how the receiver operating curve depends on the proportion of variance explained by the prediction
model (varied between 5% and 30%, indicated by line colour); the AUC (area under receiver operating curve) for each line is provided in
parentheses.
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Discussion
We have shown how knowledge of h2L, the total proportion of
liability variation explained by common SNPs, tells us a large
amount about the genetic architecture of the trait under consid-
eration. Although we have focused on epilepsy, the same tech-
niques can be used to improve our understanding of any disease.
We have estimated that h2L is at least 26% for the phenotype all
epilepsy and 27% for focal epilepsy, in both cases indicating that
common SNPs explain the majority of heritability. By combining
results from association and SNP-based heritability analysis, we
have provided evidence that epilepsy has many hundreds of sus-
ceptibility loci, and that studies comprising tens of thousands of
samples and examining the genome in higher resolution (e.g.
through full sequencing or via imputation against more compre-
hensive reference panels) will be required before we can expect to
discover a reasonable number of susceptibility loci through single-
SNP analyses.
Heritability analysis can also be used to investigate the genetic
concordance between subtypes. We have demonstrated that focal
and non-focal epilepsy have distinct genetic architectures, reinfor-
cing the view that epilepsy is a genetically heterogeneous trait and
that association analyses should take account of clinically defined
subtypes; but at the same time, we also found significant overlap
between the two subtypes, meaning there is room for subtype
definitions to be improved. Ideally, we would have considered
subtypes more specific than the two broad categories considered
here, but this was not feasible with the sample size available, thus
emphasizing the importance of enhanced scientific collaboration to
better understand the relationships between the many clinically
defined epilepsy subtypes.
h2L provides an upper bound for r
2
L , the performance of linear
prediction models based on common SNPs. Although for polygenic
traits it is unrealistic to expect to achieve r2L very close to h
2
L (or,
equivalently, r2
O
close to h2
O
), with large samples sizes, it should
be possible to make reasonable progress. For example, for human
height, h2
O
has been estimated to be 0.45 (Yang et al., 2010),
and r2
O
= 0.36 has been achieved (Makowsky et al., 2011). If,
relatively speaking, we are able to do even half as well for
epilepsy, the resulting prediction model would explain 10% of
liability variation and could be used, along with clinical factors, to
identify which single-seizure patients are at high risk of experien-
cing subsequent seizures, therefore satisfying the risk-based def-
inition of epilepsy recently adopted by the ILAE, and are likely to
benefit from immediate treatment with anti-epileptic medication.
We have taken care to avoid overestimating h2L. In particular, we
recognize that even with stringent quality control, genotyping errors
can inflate estimates; for this reason, we have proposed a way to
assess and adjust for this effect that we recommend using alongside
an existing check for inflation due to population structure and re-
sidual relatedness (Speed et al., 2012). There are many factors that
might lead to underestimation of variance explained. For example,
for prevalences similar to that of epilepsy, we have found that the
liability transformation, relied upon for converting values between
the observed and liability scale, can result in underestimation of h2L
by about a tenth. A more subtle effect comes from the implicit
assumption that the population controls are epilepsy-free.
However, even supposing 0.5% of controls (26 individuals) actually
have epilepsy, we show that our estimate of h2L would be only
1 (1 0.005)2 1% lower than the true value (see Appendix 1
and Supplementary Fig. 9). Imputing genotypes increased our esti-
mate of h2L by about a quarter. However, despite the high coverage
of the 1000 Genome reference panel, it remains that some causal
variation will be missed or only partially tagged.
Finally, it should be remembered that while we have focused on
common SNPs, these will partially tag rare causal variants, and so
our estimate of h2L will include a contribution from these (Dickson
et al., 2010). Similarly, although we assume a linear model, we can
still detect additive components of effects that are dominant or
epistatic (Zuk et al., 2012). However, for many applications, how
much of h2L is truly attributable to common variation, rather than
rare variants and epistasis, is of little importance. For example, our
ability to detect a rare causal variant through a GWAS depends not
on how much variance the causal variant explains directly, but on
the variance explained by the best tagging common SNP, and like-
wise for loci harbouring interactions. Similarly, the success of a
prediction model is how much variation it explains, not the accur-
acy of the individual effect size estimates.
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Appendix 1
Details of methods and quality control
steps
Estimating the number of causal variants
h2
O
indicates the proportion of phenotypic variance explained (on
the observed scale) by common SNPs. For each source of causal
variation, let h2j denote the variance explained by the SNP best
tagging this source of variation. We considered four distributions
for h2j : equal, uniform (with lower bound zero), exponential and
‘2’ (a gamma distribution with shape parameter 0.5). Each distri-
bution was uniquely determined by the number of causal SNPs:
given that there are J causal SNPs, we supposed the jth has
h2j = F
1(j / (1 + J), where F is the cumulative density function of
the assumed distribution (however, we checked that results were
very similar if instead values of h2j were drawn at random from the
distribution). Given h2j , the corresponding test statistic from
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standard linear regression has a 2 distribution with non-centrality
parameter nh2j /(1 h2j ), where n is the sample size. Knowing this,
we can calculate Pj, the probability that the SNP surpasses a given
significance threshold, and in turn P* =
Q
(1 Pj), the probability
that no SNP achieves significance. Note that we have assumed a
model where each causal variant is tagged by only one SNP, when
in reality each is likely to be tagged multiple times. Therefore, we
are likely to under-estimate Pj (albeit only slightly, as the set of SNPs
tagging each causal variant will be highly correlated), and in turn
will tend to under-estimate the number of causal variants required
to achieve P*40.5 or P*40.05.
Performance of prediction models
We generated prediction models empirically. For example, to con-
struct a prediction model explaining 10% of liability heritability,
we first sampled predicted values, Gi, for 1 000 000 individuals
from a Gaussian distribution with mean 0 and variance 0.1, then
generated liability values, Li, by adding to each Gi a Gaussian error
term with mean 0 and variance 0.9. Individuals with
Li4T
1(0.995) = 2.58 were cases, the remainder were controls
(T represents the cumulative density function of the standard
normal distribution). To consider population prediction, all indivi-
duals were considered. To consider prediction for single-seizure
individuals, we focused on a subset containing 45% cases (the
average proportion of single-seizure individuals who will experi-
ence a second seizure; Berg et al., 2010). For the best case sce-
nario, we picked controls at random; for the worst case scenario,
the controls were individuals with T1(0.99)5 Li5T
1(0.995),
i.e. liability values just below the case/control threshold.
Dilution of heritability
Suppose for a trait that the total proportion of phenotypic variance
explained by common SNPs is h2. We show theoretically in the
Supplementary material and through simulation in Supplementary
Fig. 9, that if a proportion p of controls have been wrongly labelled
as cases, and a proportion p’ of cases are in fact controls, then the
estimate of variance explained will reduce to (1 p p’)2 h2.
Inflation due to genotyping errors
Suppose the control samples come from two datasets, of sizes n1
and n2. In Supplementary Note 2, we show that the estimate of
total variance explained can be written as(1)
h2 ¼ nAnU
n2
T þ n
2
1
n2U
G1 þ n
2
2
n2U
G2
 2
ð1Þ
where T denotes the true proportion of phenotypic variance
explained, while G1 and G2 correspond to inflation due to geno-
typing errors within control data sets 1 and 2. It follows that if we
were to perform heritability analysis using only control data set 1
and cases, then using only control data set 2 and cases, the cor-
responding estimates of variance explained are expected to equal
h21 ¼
nAn1
ðnA þ n1Þ2
ðT þ G1Þ and h22 ¼
nAn2
ðnA þ n2Þ2
ðT þ G2Þ:
Therefore, based on estimates of h2, h21 and h
2
2, we are able to
estimate T, G1 and G2, from which our heritability estimate
adjusted for genotyping errors within controls is nAnUT/n
2. We
demonstrate the effectiveness of this approach through simulation
in Supplementary Fig. 6. The method can readily be extended to
accommodate additional control and case datasets.
Data quality control
Our raw data set comprised 5667 controls used by The Wellcome
Trust Case Control Consortium (2930 from the 1958 Birth Cohort
and 2737 from the National Blood Service) and 1485 cases. For
cases (genotyped on Illumina 660Q), we excluded samples with
average heterozygosity outside [0.281, 0.299] (44 samples
removed) or missing values for 42% of genotypes (11 additional
samples removed). To check the quality of the Illumina sequen-
cing, we re-genotyped 30 SNPs using a Sequenom array, and
excluded samples with three or more mismatches (five additional
samples removed). Finally, we excluded 64 further samples that
seemed to be duplicates (estimated kinship 40.9 with another
sample). For the controls (genotyped on Illumina 1.2 M), we fol-
lowed the recommendations of the Wellcome Trust, excluding 231
samples from the 1958 Birth Cohort and 236 from the National
Blood Service, then checked that no individuals remained with
extreme heterozygosity, missingness or evidence for duplication.
We next ensured there were no pairs of individuals with estimated
kinship 40.1875 (15 samples lost), then removed 36 potential
outliers identified through principal component analysis. Finally,
to reduce the levels of relatedness to those expected by chance,
we filtered 83 samples so that no pair remained with estimated
kinship 40.026, the absolute value of the minimum observed
(Yang et al., 2010). At this point, there remained 5129 controls
and 1298 cases (of which 958 were focal, 151 were generalized
and 149 were unclassified, whereas 40 had status unknown and
were excluded from subsequent analyses). Further phenotypic
details are provided in Supplementary Table 1, and a principal
component plot is provided in Supplementary Fig. 10.
Before imputation, we excluded SNPs with minor allele fre-
quency 50.01, call rate 50.95, or P4106 from a test for
Hardy-Weinberg Equilibrium. We imputed against the 1000
Genome June 2011 (interim) reference panel using IMPUTE2
with default parameter values (The 1000 Genomes Project
Consortium, 2010; Howie et al., 2011). Before association and
heritability analysis, we performed SNP quality control a second
time, removing those with (expected) minor allele frequency
50.01, (expected) call rate 50.995, INFO 50.98 or, if a geno-
typed SNP, r2 50.95 (the latter two metrics are scores computed
by IMPUTE2). These thresholds are much stricter than those typi-
cally used for marginal association analysis. However, with herit-
ability analysis, it is necessary to be far more cautious, especially
when cases and controls have been genotyped separately, as even
slight errors can accumulate over SNPs to produce greatly inflated
estimates of variance explained (Yang et al., 2011; Speed et al.,
2012). For heritability analysis, we used the remaining 4 238 038
autosomal SNPs, of which 299 735 were directly genotyped. For
the association analysis, we additionally considered the 89 281
SNPs passing quality control on chromosome X.
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